Action of calcium antagonists and agonists on isolated human thoracic arteries used for coronary artery bypass grafting

Pharmacological Reports

Volumn 64, Issue 3, 2012, Pages 733-738

  Garaliene, Vida ^a   Barsys, Vygantas ^a   Jakuška, Povilas ^b   Benetis, Rimantas ^b  

^a LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^b LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

Author keywords

1 acetyl 5; 4 dihydropyridine type; 6 dimethoxy 2 methylthiobenzimidazole; Calcium channel agonists and antagonists 1; Human thoracic artery

Indexed keywords

1 ACETYL 5,6 DIMETHOXY 2 METHYLTHIOBENZIMIDAZOLE; 4 [2 (DIFLUOROMETHOXY)PHENYL] 1,4,5,7 TETRAHYDRO 2 METHYL 5 OXOFURO[3,4 B]PYRIDINE 3 CARBOXYLIC ACID ETHYL ESTER; AMLODIPINE; BENZIMIDAZOLE DERIVATIVE; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM ION; CARBACHOL; CEREBROCRAST; DILTIAZEM; PHENYLEPHRINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERY CONSTRICTION; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTICLE; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; HUMAN TISSUE; HYPERPOLARIZATION; MAJOR CLINICAL STUDY; MALE; MAMMARY ARTERY; MUSCLE ISOMETRIC CONTRACTION; SMOOTH MUSCLE CONTRACTION;

EID: 84866101894     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(12)70868-X     Document Type: Article

References (26)

1. Bauersachs J, Widder JD: Endothelial dysfunction in heart failure. Pharmacol Rep, 2008, 60, 119-126.
2. Coleman HA, Tare M, Parkington HC: Endothelial potassium channels, endothelium-dependent hyperpolarization and the regulation of vascular tone in health and disease. Clin Exp Pharmacol Physiol, 2004, 31, 641-649.
3. Dalsgaard T, Kroigaard C, Simonsen U: Calcium-activated potassium channels - a therapeutic target for modulating nitric oxide in cardiovascular disease? Expert Opin Ther Targets, 2010, 14, 825-837.
4. Doughan AK, Harrison DG, Dikalov SI: Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res, 2008, 102, 488-496.
5. Feletou M: Calcium-activated potassium channels and endothelial dysfunction: therapeutic options? Br J Pharmacol, 2009, 156, 545-562.
6. Francis SH, Büsch JL, Corbin JD, Sibley D: cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev, 2010, 62, 525-563.
7. Garaliene V, Barsys V, Jakuška P, Krauze A, Dubur G: Effects of calcium antagonists and agonists on isolated human v. saphena magna used for coronary artery bypass grafting and guinea pig's papillary muscle. Arzneimittelforschung, 2011, 61, 386-392.
8. Garaliene V, Labanauskas L, Brukštus A: Effect of 1-acyl-5,6-dialkoxy-2-aklylthiobenzod.imidazoles on the action potential duration and isometric contraction in guinea pig atrium activated by carbachol and guinea heart papillary muscles. Arzneimittelforschung, 2006, 282-287.
9. Ca) and arteriolar myogenic signaling. FEBS Lett, 2010, 584, 2033-2042.
10. 45Ca uptake by rat uterine segments. Japan J Pharmacol, 1991, 56, 397-402.
11. Jackson WF: Potassium channels in the peripheral microcirculation. Microcirculation, 2005, 12, 113-127.
12. Knollmann BC: New roles of calsequestrin and triadin in cardiac muscle. J Physiol, 2009, 587, 3081-3087.
13. 2+ release. Br J Pharmacol, 1987, 92, 499-504.
14. Kocić I, Ruczyński J, Szczepańska R, Olkowicz M, Parfianowicz B, Rusiecka I, Rekowski P: Cell-penetrating peptides modulate the vascular action of phenylephrine. Pharmacol Rep, 2011, 63, 195-199.
15. Landmesser U, Hornig B, Drexler H: Endothelial function: a critical determinant in atherosclerosis? Circulation, 2004, 109, Suppl 1, II27-33.
16. 2+ cycling and new therapeutic approaches for heart failure. Circulation, 2010, 121, 822-830.
17. Matsumoto T, Kobayashi T, Kamata K: Phosphodiesterases in the vascular system. J Smooth Muscle Res, 2003, 39, 67-86.
18. Monnink SH, Tio RA, van Boven AJ, van Gilst WH, van Veldhuisen DJ: The role of coronary endothelial function testing in patients suspected for angina pectoris. Int J Cardiol, 2004, 96, 123-129.
19. 2+ sparks is involved in regulation of arterial diameter by cyclic nucleotides. Am J Physiol Cell Physiol, 1998, 274, C1346-C1355.
20. 2+ sparklets in smooth muscle. J Mol Cell Cardiol, 2009, 47, 436-444.
21. + channels directly control agonist-evoked nitric oxide synthesis in human vascular endothelial cells. Am J Physiol Cell Physiol, 2007, 293, C458-C467.
22. + (SK3) channels modulates arterial tone and blood pressure. Circ Res, 2003, 93, 124-131.
23. Thompson PE, Manganiello V, Degerman E: Re-discovering PDE3 inhibitors - new opportunities for a long neglected target. Curr Top Med Chem, 2007, 7, 421-436.
24. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S: Endothelium-dependent contractions and endothelial dysfunction in human hypertension. Br J Pharmacol, 2009, 157, 527-536.
25. Zakharenko SS, Reznik AV: Mechanisms of vascular wall calcium relaxation. Membr Cell Biol, 1988, 12, 441-451.
26. Zhang XP, Tada H, Wang Z, Hintze TH: cAMP signal transduction, a potential compensatory pathway for coronary endothelial NO production after heart failure. Arterioscler Thromb Vasc Biol, 2002, 22, 1273-1278.